Cervical cancer is the second most common cancer in the world, and the majority of those who die from cervical cancer are under screened women in developing countries with a healthcare system lacking in infrastructure, funding, access, and skilled personnel (1).
QIAGEN’s careHPV Test was designed with these women in mind. It allows testing for high-risk HPV in limited resource settings and can be used for primary, stand-alone screening in women 30 years and older to determine high-risk HPV infection, which is a risk factor for developing cervical cancer (2).
The careHPV Test can be run by a healthcare worker with proper training and no formal laboratory skills are required. The test may be run on electricity or on a battery with an inverter, making it portable and adaptable. The test can be run in a flexible temperature range, from 15°C to 40°C.
The careHPV Test is a nucleic acid hybridization assay with signal amplification that uses microplate chemiluminescence for the qualitative detection of 14 high-risk types of HPV DNA in cervical and vaginal specimens. The HPV types detected by the assay are the high-risk HPV DNA types 16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Individual HPV types cannot be determined using this test. The careHPV Test is CE-marked for use as an in vitro diagnostic test.
The careBrush, careHPV Collection Medium, and the careHPV Test are CE-marked for in vitro diagnostic use. Not available in all countries.
CARE is a registered trademark of COOPERATIVE FOR ASSISTANCE AND RELIEF EVERYWHERE, INC. (“CARE”). CARE and the members and affiliates of CARE International are not affiliated with QIAGEN and do not sponsor, endorse, support, participate in or control the development, manufacture, use or sale of any QIAGEN product.